Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RIC Allo-HSCT with Tacrolimus/MMF for Hematologic Malignancies
NCT02661035Phase 2Completed
- Sponsor
- Masonic Cancer Center
- Start
- Mar 2017
- Primary completion
- Apr 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of tacrolimus + Wuzhi capsule, mycophenolate mofetil in hematologic malignancy, sponsored by Masonic Cancer Center. Started Mar 2017; status: completed.
02
Drugs
tacrolimus + Wuzhi capsulemycophenolate mofetil
03
Conditions
hematologic malignancy
Beyond the preview
Go deeper on NCT02661035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02661035.